Moderna, Inc.’s request for US emergency use authorization of a second COVID-19 vaccine booster shot in the general adult population marks the company’s first bid to move past rivals Pfizer Inc./BioNTech SE in breadth of indication for the competing mRNA products.
On 17 March, Moderna announced it had submitted a request to the Food and Drug Administration for an additional booster...







